Volume 30, Number 11—November 2024
Dispatch
Emerging Monkeypox Virus Sublineage C.1 Causing Community Transmission, Vietnam, 2023
Huynh Thi Thuy Hoa, Nguyen Thanh Dung
, Le Manh Hung, Nguyen Thi Thu Hong, Vo Truong Quy, Nguyen Thi Thao, Nguyen Trong Duy, Hoang Truong, Tran Minh Hoang, Nguyen Thi Thanh, Mai Pham Hong Phuoc, Truong Ngoc Trung, Nguyen Nhut Thong, Nguyen Duc Huy, Vu Thi Kim Thoa, Vo Trong Vuong, Ngo Tan Tai, Huynh Kim Nhung, Dao Phuong Linh, Pham Thi Ngoc Thoa, Lam Minh Yen, Tran Ba Thien, Truong Hoang Chau Truc, Le Kim Thanh, Nguyen Thi Han Ny, Vo Tan Hoang, Nghiem My Ngoc, Dinh Nguyen Huy Man, Louise Thwaites, Tran Tan Thanh, Nguyen Van Vinh Chau, Guy Thwaites, Nguyen To Anh, and Le Van Tan
, Le Manh Hung, Nguyen Thi Thu Hong, Vo Truong Quy, Nguyen Thi Thao, Nguyen Trong Duy, Hoang Truong, Tran Minh Hoang, Nguyen Thi Thanh, Mai Pham Hong Phuoc, Truong Ngoc Trung, Nguyen Nhut Thong, Nguyen Duc Huy, Vu Thi Kim Thoa, Vo Trong Vuong, Ngo Tan Tai, Huynh Kim Nhung, Dao Phuong Linh, Pham Thi Ngoc Thoa, Lam Minh Yen, Tran Ba Thien, Truong Hoang Chau Truc, Le Kim Thanh, Nguyen Thi Han Ny, Vo Tan Hoang, Nghiem My Ngoc, Dinh Nguyen Huy Man, Louise Thwaites, Tran Tan Thanh, Nguyen Van Vinh Chau, Guy Thwaites, Nguyen To Anh, and Le Van Tan
Table
Baseline characteristics of 25 participants in study of emerging monkeypox virus sublineage C.1 causing community transmission, Vietnam, 2023*
| Characteristic | Value |
|---|---|
| Median age, y (range) | 31 (22–49) |
| From Ho Chi Minh City | 20/25 (80) |
| Median time from symptom onset to admission, d (range) | 6 (4–30) |
| Median hospitalization, d (range) | 14 (11–43) |
| Sexual activity within 21 d before illness | 18/25 (72) |
| Travel abroad within 21 d before illness | 0/25 (0) |
| HIV-positive | 21/25 (84) |
| Receiving antiretroviral therapy | 16/21 (76) |
| Gonorrhea | 5/25 (20) |
| Syphilis |
9/25 (36) |
| Symptoms | |
| Fever | 14/25 (56) |
| Sore throat | 5/25 (20) |
| Myalgia | 2/25 (8) |
| Headache | 1/25 (4) |
| Fatigue | 2/25 (8) |
| Oral pain | 2/25 (8) |
| Diarrhea | 2/25 (8) |
| Rectal pain | 6/25 (24) |
| Pain with swallowing | 2/25 (8) |
| Difficulty swallowing | 1/25 (4) |
| Lymphadenopathy | 16/25 (64) |
| Cervical | 9/16 (56) |
| Inguinal |
9/16 (56) |
| Median temperature, °C (range) | 37 (37–38.5) |
| Median heart rate, bpm (range) | 85 (75−130) |
| Median respiratory rate, bpm (range) | 20 (18–22) |
| Median arterial pressure, mm Hg (range) |
83 (73–107) |
| Laboratory findings, median (range)/(reference range) | |
| CD4+ count, cells/µL | 451 (1–956)/(500–1600) |
| leukocyte count, 109 cells/L | 9.98 (5.53–17.08)/(4.5–11) |
| Hemoglobin, g/L | 147 (11–174)/(130–160) |
| Platelet count, 109/L | 256 (131–473)/(140–440) |
| Glucose, mg/dL | 83 (6–138)/(70–100) |
| Aspartate aminotransferase, U/L | 24 (15–48)/(0–40) |
| Alanine aminotransferase, U/L | 35 (11–85)/(0–40) |
| Creatinine, µmol/L |
89 (70–147)/(53–120) |
| No. lesions | |
| 1–5 | 1/25 (4) |
| 6–25 | 11/25 (44) |
| 26–100 | 12/25 (48) |
| >250 |
1/25 (4) |
| Lesion position | |
| Arm | 20/25 (80) |
| Leg | 19/25 (76) |
| Genitals | 19/25 (76) |
| Oral mucosa | 5/25 (20) |
| Perianal area |
15/25 (60) |
| Lesion characteristics | |
| Macule | 5/25 (20) |
| Papule | 6/25 (24) |
| Early vesicle | 11/25 (44) |
| Small pustule | 21/25 (84) |
| Umbilicated pustule | 12/25 (48) |
| Ulcerated lesion | 6/25 (24) |
| Crusting of a mature lesion | 10/25 (40) |
| Partially removed scab | 3/25 (12) |
*Values are no. (%) unless otherwise indicated. All patients were assigned male sex at birth; 24/25 reported having sex with men (2 men identified as bisexual). No participants had been vaccinated for mpox or had a tecovitimat prescription.
Page created: September 05, 2024
Page updated: October 22, 2024
Page reviewed: October 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.